Beryl Drugs Ltd
Beryl Drugs Ltd is principally engaged in Manufacturing of Bulk Drugs. It was incorporated in 1993.[1]
- Market Cap ₹ 15.3 Cr.
- Current Price ₹ 30.1
- High / Low ₹ 45.0 / 14.2
- Stock P/E 19.8
- Book Value ₹ 17.6
- Dividend Yield 0.00 %
- ROCE 11.0 %
- ROE 9.07 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 26.4%
- Company has a low return on equity of 3.70% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14.42 | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 27.13 | |
13.50 | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.46 | |
Operating Profit | 0.92 | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.67 |
OPM % | 6.38% | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 9.84% |
0.12 | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.00 | |
Interest | 0.14 | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.46 |
Depreciation | 0.29 | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 |
Profit before tax | 0.61 | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 |
Tax % | 36.07% | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% |
0.39 | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | |
EPS in Rs | 0.76 | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 16% |
3 Years: | 25% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | 113% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 38% |
3 Years: | 41% |
1 Year: | 96% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 2% |
3 Years: | 4% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.06 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
Reserves | 1.06 | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 |
0.89 | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | |
1.92 | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | |
Total Liabilities | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 |
2.85 | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | |
CWIP | 0.00 | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 1.24 | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 |
4.84 | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | |
Total Assets | 8.93 | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.78 | 0.00 | 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.29 | 2.48 | 0.82 | |
-0.70 | 0.00 | 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.54 | -1.30 | -1.08 | |
0.08 | 0.00 | -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.43 | -1.17 | 0.10 | |
Net Cash Flow | 0.16 | 0.00 | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 56.70 | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 101.98 |
Inventory Days | 30.75 | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | 35.00 | |
Days Payable | 52.72 | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | 56.11 | |
Cash Conversion Cycle | 34.73 | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 80.87 |
Working Capital Days | 35.69 | 75.56 | 84.70 | 105.37 | 120.89 | 105.53 | 43.59 | 82.25 | 120.45 | 138.39 | 71.26 | 93.23 |
ROCE % | 11.59% | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% |
Documents
Announcements
- Compliance-57 (5) : intimation after the end of quarter 8 Jul
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Jul - CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DP) REGULATIONS, 2018 FOR THE QUARTER ENDED 30.06.2024
- Closure of Trading Window 30 Jun
- Announcement under Regulation 30 (LODR)-Newspaper Publication 31 May
- AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2024 30 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Offerings
The company offers a broad range of manufacturing options to clients such as small volume injectables in liquid and dry power form, variety of eye and ear drops, IV Fluids in polypack and glass bottles and variety of veterinary medicines.[1]